JPH05236872A - Food containing lactic acid bacterium - Google Patents

Food containing lactic acid bacterium

Info

Publication number
JPH05236872A
JPH05236872A JP4075623A JP7562392A JPH05236872A JP H05236872 A JPH05236872 A JP H05236872A JP 4075623 A JP4075623 A JP 4075623A JP 7562392 A JP7562392 A JP 7562392A JP H05236872 A JPH05236872 A JP H05236872A
Authority
JP
Japan
Prior art keywords
lactic acid
acid bacterium
mutagen
food
antimutagenicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4075623A
Other languages
Japanese (ja)
Inventor
Hideo Hashimoto
英夫 橋本
Masataka Hosoda
正孝 細田
Midori Chiba
みどり 千葉
Hirotsugu Morita
裕嗣 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAKANASHI NYUGYO KK
Original Assignee
TAKANASHI NYUGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAKANASHI NYUGYO KK filed Critical TAKANASHI NYUGYO KK
Priority to JP4075623A priority Critical patent/JPH05236872A/en
Publication of JPH05236872A publication Critical patent/JPH05236872A/en
Pending legal-status Critical Current

Links

Landscapes

  • Non-Alcoholic Beverages (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

PURPOSE:To obtain the subject food, comprising lactic acid bacteria having antimutagenicity against mutagens, excellent in safety and health retaining effects and useful as a fermented milk, a lactic acid bacteria beverage, etc. CONSTITUTION:The objective food comprises lactic acid bacteria such as Lactobacillus.casei having antimutagenicity against mutagens such as a base substitution type mutagen or a frame shift type mutagen.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、抗変異原性を有する乳
酸菌を含有する食品に関し、さらに詳細には、変異原物
質に対し高い抗変異原性を有し、健康食品、保健用食品
等として有利に利用することのできる発酵乳、乳酸菌飲
料等の食品に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a food containing lactic acid bacteria having antimutagenicity, and more specifically, it has a high antimutagenicity against mutagens and is a health food, a food for health use, etc. The present invention relates to foods such as fermented milk and lactic acid bacterium beverages that can be advantageously used as.

【0002】[0002]

【従来の技術およびその課題】我々が日常的に摂取して
いる食品は、安全性の面ではかなり低リスクのものであ
ると見なすことができる。 しかし、食品中には数多く
の変異原物質が含まれる可能性があり、この物質はガン
発症に深いかかわりを持っている点で今日大きな関心が
寄せられている。
2. Description of the Related Art The foods that we eat on a daily basis can be regarded as having a considerably low risk in terms of safety. However, many mutagens can be contained in foods, and these substances are of great interest today because they are deeply involved in the onset of cancer.

【0003】変異原物質として現在知られているもの
は、肉や魚の焼け焦げの部分に含まれる、3−アミノ−
1−メチル−5H−ピリド[4,3−b]−インドール
(以下、「Trp−P−2」と略称する)、魚と野菜の
食べあわせにより生成するニトロソ化合物、食品に生え
たカビの代謝産物として生成するアフラトキシン等であ
る。
The currently known mutagen is 3-amino-, which is contained in the burnt parts of meat and fish.
1-Methyl-5H-pyrido [4,3-b] -indole (hereinafter abbreviated as "Trp-P-2"), nitroso compound produced by eating fish and vegetables, metabolism of mold growing in food Aflatoxins and the like produced as products.

【0004】これらの変異原物質の多くは発ガン物質で
あることが既に判明しており、突然変異毒性の観点か
ら、人体細胞の癌化や老化に深い関係があるこれら変異
原物質を食品中から除去することが望まれている。
It has already been found that many of these mutagens are carcinogens, and from the viewpoint of mutation toxicity, these mutagens that are deeply related to carcinogenesis and aging of human somatic cells are contained in foods. To be removed from

【0005】従来、食品中からこれらの変異原物質を除
去する方法としては、酵素を利用する方法が知られてお
り、例えば、コーヒーにペルオキシダーゼを作用せしめ
る方法(特開昭60−62945号)、コーヒーにカタ
ラーゼを作用せしめる方法(特開昭59−232049
号)、ビタミンC製剤にカタラーゼを作用せしめる方法
(特開昭60−54317号)などが報告されている。
また、乳酸菌食品に関しては、10℃以下の乳酸菌発
酵液に、パーオキシダーゼとチオシアン酸イオンおよび
/またはハロゲノンイオンを有する系を添加する乳酸菌
発酵食品の製造法(特公昭62−228224号)があ
り、これにより変異原物質や発ガン物質が除去しうると
報告されている。
Conventionally, a method utilizing an enzyme has been known as a method for removing these mutagens from foods, for example, a method in which peroxidase is allowed to act on coffee (JP-A-60-62945), Method of causing catalase to act on coffee (Japanese Patent Laid-Open No. 59-232049)
No.), a method of allowing catalase to act on a vitamin C preparation (JP-A-60-54317), and the like.
Regarding the lactic acid bacterium food, there is a method for producing a lactic acid bacterium fermented food in which a system having a peroxidase and a thiocyanate ion and / or a halogenone ion is added to a lactic acid bacterium fermentation liquid at 10 ° C or lower (Japanese Patent Publication No. 62-228224). , It has been reported that this can remove mutagens and carcinogens.

【0006】一方、前記のような変異原物質と発ガンの
関連性から、食品中の抗変異原性因子の有無は、栄養
性、消化性、安全性、風味性といった食品の価値を決め
る諸要因と並んで極めて重要であるとされている。
On the other hand, based on the above-mentioned relationship between mutagens and carcinogenesis, the presence or absence of antimutagenic factors in foods determines the value of foods such as nutrition, digestibility, safety and flavor. It is said to be extremely important along with the factors.

【0007】近年、多くの研究者によって抗変異原性を
もった種々の食品が報告されており、牛乳、乳製品、生
野菜、果物、高繊維食品、高ビタミン含有食品などがそ
の例とされている。 そして、これらの食品は、単に発
ガン性のリスクが低い食品という見方より、健康保持機
能の高い食品と位置づけられている。
In recent years, many researchers have reported various antimutagenic foods, such as milk, dairy products, raw vegetables, fruits, high fiber foods, and high vitamin content foods. ing. Further, these foods are regarded as foods having a high health-retaining function, rather than simply foods having a low risk of carcinogenicity.

【0008】特に発酵乳には、食品に含まれる変異原物
質の影響を減弱させる性質があることが報告されている
[細野明義:酪農科学・食品の研究 Vol.35 No.6 A-283
〜A-289(1986)]。
In particular, it has been reported that fermented milk has a property of reducing the effect of mutagens contained in foods [Hosono Akiyoshi: Dairy Science / Food Research Vol.35 No.6 A-283].
~ A-289 (1986)].

【0009】しかしながら、現在市販されている発酵乳
や、乳酸菌入り飲料について抗変異原性の有無を調べる
と、ほとんどないか、あっても極めて弱いものであっ
た。
However, when the presence or absence of antimutagenicity in fermented milk and beverages containing lactic acid bacteria, which are currently on the market, was examined, it was found to be little or very weak.

【0010】[0010]

【課題を解決するための手段】本発明者は、発酵乳にお
いて報告されている抗変異原性について、その原因を探
索したところ、これが単に乳酸菌の乳酸生成にともなう
pH低下によっておこる変異原物質の失活が原因ではな
く、発酵に用いる菌体が強く関与しているとの示唆を得
た。 そこで更に検討を進めていたところ、乳酸菌中に
は特異的に高い抗変異原性を有する1群の微生物が存在
すること、およびこれを乳酸菌として発酵乳等の食品に
配合すれば高い抗変異原性を有する、健康食品、保健用
食品としての積極的効果を奏する食品が得られることを
見出し、本発明を完成した。
Means for Solving the Problems Regarding the antimutagenicity reported in fermented milk, the present inventor searched for the cause and found that the cause of the mutagen caused simply by the pH decrease accompanying the lactic acid production of lactic acid bacteria. It was suggested that the bacterial cells used for fermentation are strongly involved, not the inactivation. As a result of further studies, it was found that a group of microorganisms having high antimutagenicity specifically exists in lactic acid bacteria, and that if they are added to foods such as fermented milk as lactic acid bacteria, high antimutagenicity can be obtained. It was found that a food having a positive effect as a health food or a health food can be obtained, and the present invention was completed.

【0011】すなわち本発明は、変異原物質に対する抗
変異原性を有する乳酸菌を含有する食品を提供するもの
である。
That is, the present invention provides a food containing a lactic acid bacterium having antimutagenicity against a mutagen.

【0012】本発明の食品に使用される乳酸菌(以下、
「抗変異原性乳酸菌」という)は、天然中あるいは種々
の発酵乳中から、例えば以下に示すスクリーニング法に
より分離・採取することができる。 なお、本明細書に
おいて、「乳酸菌」とは、乳酸発酵を行なうことのでき
る全ての微生物を指称し、ラクトバチルス属微生物、ラ
クトコカッス属微生物、ストレプトコッカス属微生物、
エンテロコッカス属微生物、ビフィドバクテリウム属微
生物等を含むものである。また、本明細書において「抗
変異原性」とは、変異原物質が与える影響を抑制し、減
弱するようなすべての作用をいい、変異原物質自体を不
活性化するような作用も含む。
The lactic acid bacteria used in the food of the present invention (hereinafter,
The "anti-mutagenic lactic acid bacterium") can be isolated and collected from the nature or various fermented milks, for example, by the following screening method. In the present specification, "lactic acid bacterium" refers to all microorganisms capable of lactic acid fermentation, Lactobacillus microorganisms, Lactococcus microorganisms, Streptococcus microorganisms,
It includes a microorganism belonging to the genus Enterococcus, a microorganism belonging to the genus Bifidobacterium, and the like. In the present specification, the term "antimutagenicity" refers to all the effects of suppressing and reducing the effects of the mutagen, and also includes the effect of inactivating the mutagen itself.

【0013】本発明で使用される乳酸菌のスクリーニン
グは、まず乳酸菌を含む試料、例えば発酵乳から乳酸菌
のコロニーを分離した後、釣菌し、これを純粋培養して
試験乳酸菌株を得る。 ついで、試験乳酸菌株を適当な
菌数、例えば2〜3億個/ml程度に調製し、これに変
異原物質、例えばN−メチル−N'−ニトロ−N−ニト
ロソグアニジン(以下、「MNNG」と略称する)、T
rp−P−2、アフラトキシン、ベンツピレン等を加
え、更に、必要に応じてS9−mixを加える。この
後、突然変異検定菌、例えばサルモネラ・チフィムリウ
ム(Salmonella typhimurium)TA100株やTA9
8株、あるいは大腸菌(Escherichia coli)WP2uv
rAなどを添加し、この混合物をプレインキュベートし
たのち、更に固体培地中で適当な時間培養する。 培養
終了後、突然変異検定菌に生じた復帰突然変異コロニー
を検出し、当該コロニー数から各試験乳酸菌の抗変異原
性作用を評価し、抗変異原性の高い乳酸菌を選択すれば
良い。
In the screening of lactic acid bacteria used in the present invention, first, a lactic acid bacterium colony is separated from a sample containing lactic acid bacterium, for example, fermented milk, and then the bacterium is picked and the lactic acid bacterium is purely cultured to obtain a test lactic acid bacterium strain. Then, a test lactic acid bacterium strain is prepared in an appropriate number of bacteria, for example, about 300 to 300 million cells / ml, and a mutagen such as N-methyl-N′-nitro-N-nitrosoguanidine (hereinafter, referred to as “MNNG”) is prepared. For short), T
rp-P-2, aflatoxin, benzpyrene and the like are added, and further S9-mix is added if necessary. This is followed by a mutation test strain, such as Salmonella typhimurium TA100 strain or TA9.
8 strains or Escherichia coli WP2uv
After adding rA or the like and pre-incubating the mixture, the mixture is further cultured in a solid medium for an appropriate time. After completion of the culture, a revertant colony produced in the mutant assay strain may be detected, the antimutagenic action of each test lactic acid bacterium may be evaluated from the number of the colonies, and a lactic acid bacterium with high antimutagenicity may be selected.

【0014】上記試験に際しては、ポジティブコントロ
ール(変異原物質、S9−mix、突然変異検定菌のみ
のもの)、これから変異原物質を除いたスタンダードコ
ントロールおよび試験乳酸菌のみのコントロールを設け
ることが必要である。
In the above test, it is necessary to provide a positive control (mutagen, S9-mix, mutant test bacteria only), a standard control excluding the mutagen and a control of only the test lactic acid bacterium. ..

【0015】また、上記結果から抗変異原性原率を算出
するには下記の式によればよい。 抗変異原性率 =[(B−A)/(B−C)]×100 A: 変異原物質と乳酸菌を添加したときの復帰変異体
コロニー数 B: 変異原物質のみを添加したときの復帰変異体コロ
ニー数 C: 乳酸菌のみを添加したときの復帰変異体コロニー
Further, the following formula may be used to calculate the rate of antimutagenicity from the above results. Antimutagenicity rate = [(BA) / (BC)] x 100 A: Number of revertant colonies when mutagen and lactic acid bacteria were added B: Revert when only mutagen was added Number of mutant colonies C: Number of revertant colonies when only lactic acid bacteria were added

【0016】上記の方法により抗変異原性乳酸菌を検出
し、分離・採取できるのであるが、本発明者らの試験の
結果によれば、抗変異原性の有無は同じ乳酸菌に属する
微生物でも、菌株による違いが大きく、属または種の差
によるものでないこと、及び抗変異原性微生物の抗変異
原性も、変異原物質の種類により差があることが判明し
ている。
Although the antimutagenic lactic acid bacterium can be detected, separated and collected by the above method, according to the results of the test conducted by the present inventors, even if the microorganisms belonging to the same lactic acid bacterium are antimutagenic, It has been revealed that the strains are largely different depending on the genus or species, and that the antimutagenicity of the antimutagenic microorganism also differs depending on the type of mutagen.

【0017】本発明に使用する乳酸菌の抗変異原活性
は、上記の抗変異原性率として少なくとも1つの変異原
物質に対して40%〜55%以上であることが好まし
く、また、複数の変異原物質に対するものであることが
より望ましい。
The antimutagenic activity of the lactic acid bacterium used in the present invention is preferably 40% to 55% or more with respect to at least one mutagen in terms of the above antimutagenicity, and a plurality of mutations More preferably it is for the raw material.

【0018】本発明の食品は、上記のようにして得られ
る抗変異原性乳酸菌を用いて、例えば牛乳等の獣乳を発
酵せしめるか、あるいは通常の食品、例えば果物ジュー
ス、野菜ジュース等の中に当該乳酸菌を添加せしめるこ
とにより調製される。 前者の食品の例としては、ヨー
グルト等の発酵乳、クミス、ケフィア等の発酵酒、乳酸
菌飲料、チーズ等の発酵食品が挙げられる。 また後者
の食品の例としては乳酸菌入りジュース等が挙げられ
る。
The food of the present invention is prepared by fermenting animal milk such as milk with the antimutagenic lactic acid bacterium obtained as described above, or in ordinary foods such as fruit juice and vegetable juice. It is prepared by adding the lactic acid bacterium to. Examples of the former food include fermented milk such as yogurt, fermented liquor such as kumisu and kefir, lactic acid bacterium beverage, and fermented food such as cheese. Examples of the latter food include juice containing lactic acid bacteria.

【0019】本発明の食品の製造において、添加する抗
変異原性乳酸菌の数に制限はないが、乳酸菌数が多いほ
うがより優れた抗変異原作用を期待できるので好まし
い。この意味では、発酵により乳酸菌数を増加せしめる
ことのできる発酵食品がより好ましい。
In the production of the food of the present invention, the number of antimutagenic lactic acid bacteria to be added is not limited, but a larger number of lactic acid bacteria is preferable because a better antimutagenic effect can be expected. In this sense, fermented foods that can increase the number of lactic acid bacteria by fermentation are more preferable.

【0020】本発明食品に使用する乳酸菌は、人体の胃
酸を始め、消化酵素系、胆汁酸に対して耐性を有してい
る、いわゆる腸管到達性のある乳酸菌であることがより
好ましい。 腸管到達性のある乳酸菌が好ましい理由
は、これら腸管内においてフロラとなり、腸管に存在す
る変異原物質から腸組織を有効に保護するためである。
このような腸管到達性のある乳酸菌の例としては、ラク
トバチルス・カゼイ、ラクトバチルス・アシドフィラスお
よびビフィドバクテリウム等が挙げられる。
The lactic acid bacterium used in the food of the present invention is more preferably a so-called intestinal-reachable lactic acid bacterium which is resistant to gastric acid of the human body, digestive enzyme system and bile acid. The reason why lactic acid bacteria that can reach the intestinal tract are preferable is that they become flora in these intestinal tracts and effectively protect the intestinal tissues from the mutagens existing in the intestinal tracts.
Examples of such lactic acid bacteria capable of reaching the intestinal tract include Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium.

【0021】本発明食品の調製は、乳酸菌として抗変異
原性を有するものを用いる以外は通常の方法により実施
でき、食品の種類に応じた各種の成分や添加物、例え
ば、乳、、乳製品、砂糖等の糖類、果汁、野菜汁、ゲル
化剤、香料等を任意に加えることができる。
The food of the present invention can be prepared by a usual method except that a lactic acid bacterium having antimutagenicity is used, and various components and additives such as milk and dairy products depending on the type of food are used. , Sugars such as sugar, fruit juices, vegetable juices, gelling agents, flavors and the like can be optionally added.

【0022】[0022]

【作用】本発明食品の抗変異原性のメカニズムは解明さ
れていないが、変異原物質と抗変異原性乳酸菌との間に
存在する何等かの相互作用によるものと考えられる。
Action: The mechanism of antimutagenicity of the food of the present invention has not been clarified, but it is considered to be due to some interaction existing between the mutagen and the antimutagenic lactic acid bacterium.

【0023】[0023]

【発明の効果】後記実施例からも明かとなるように、抗
変異原性を有する乳酸菌を利用した本発明の食品は、従
来から提供されている発酵乳製品(例えばヨーグルト)
等の食品と比べ、極めて高い変異原物質の減弱化能力を
有していた。このように、本発明の食品は、変異原物質
に対し高い抗変異原活性を有するので、これを日常的に
摂取することにより、他の食品中に混入する変異原物質
の作用を抑制し、安全かつ積極的な健康保持効果が可能
となる。
EFFECTS OF THE INVENTION As will be apparent from the examples described below, the food of the present invention utilizing lactic acid bacteria having antimutagenicity is a fermented dairy product (eg yogurt) which has been conventionally provided.
It had a much higher ability to reduce mutagens compared to other foods. Thus, the food of the present invention has a high antimutagenic activity against mutagens, so by ingesting this daily, suppress the action of mutagens mixed in other foods, A safe and positive health maintenance effect becomes possible.

【0024】特に、腸管到達性の高い抗変異原性乳酸菌
を用いれば、咽喉や口腔のみならず消化管内においても
これら乳酸菌がフロラとして存在することが可能となる
ので、消化管内での発ガンの原因となる変異原物質を除
去、抑制することが十分に期待できる。
[0024] In particular, when an antimutagenic lactic acid bacterium having a high intestinal reach is used, it becomes possible for these lactic acid bacteria to exist as flora not only in the throat and oral cavity but also in the digestive tract. It can be fully expected to remove or suppress the causative mutagen.

【0025】[0025]

【実施例】次に、実施例を挙げ、本発明を更に詳しく説
明するが、本発明はこれら実施例になんら制約されるも
のでない。 実 施 例 1: 抗変異原性乳酸菌のスクリーニング:下記のスクリーニ
ング法により、抗変異原性を有する乳酸菌を選択した。 (a)各種の乳酸菌試料を各々適量サンプリングし、生
理食塩水にて希釈懸濁した後、ブロムクレゾール・パー
プル・プレート・カウント寒天培地(B.C.P培地)で塗
抹培養した。 培地上に成育したコロニーから釣菌し、
これを再度生理食塩水に懸濁し、B.C.P培地に塗抹培
養を繰り返して乳酸菌株の純粋分離を行なった。 得ら
れた乳酸菌株を、液体培地(MRS培地)中、30℃ま
たは37℃で17時間培養した。 この培養液を300
0Gの遠心分離にかけ、菌体を分離し、リン酸緩衝液
(pH7.4)で洗浄した。 この操作を3回繰り返し、
同緩衝液で菌数を2〜3億/mlとし乳酸菌調製液を得
た。
EXAMPLES Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples. Example 1 Screening of anti-mutagenic lactic acid bacteria: Lactic acid bacteria having anti-mutagenicity were selected by the following screening method. (A) Each lactic acid bacterium sample was sampled in an appropriate amount, diluted and suspended in physiological saline, and then smeared and cultured on bromcresol purple plate count agar medium (BCP medium). From the colonies that grew on the medium, pick up the bacteria,
This was resuspended in physiological saline, and smear culture was repeated in BCP medium to perform pure isolation of the lactic acid bacterium strain. The resulting lactic acid bacterium strain was cultured in a liquid medium (MRS medium) at 30 ° C or 37 ° C for 17 hours. 300 times this culture
The cells were separated by centrifugation at 0 G and washed with a phosphate buffer (pH 7.4). Repeat this operation 3 times,
A lactic acid bacterium preparation liquid was obtained by adjusting the number of bacteria to 200 to 300 million / ml with the same buffer solution.

【0026】(b)滅菌した試験管に、この乳酸菌調製
液を0.1mlとり、これに変異原物質として代表的塩
基置換型変異原物質であるMNNGを5μg/mlとな
るように加え、さらに突然変異検定菌 サルモネラ・チフ
ィムリウム(Salmonella typhimurium)TA100株を
加え、振盪培養恒温水槽中、37℃で20分間振盪し、
プレインキュベートした。 次いで、トップアガーを加
えて混合し、最少グルコース培地の上に注ぎ、一様に広
げた。 遮光し、37℃で48時間培養した後、復帰突
然変異により生じたサルモネラ・チフィムリウムのヒス
チジン非要求株のコロニーの数を数え、抗変異原性率を
算出した。
(B) To a sterilized test tube, take 0.1 ml of this lactic acid bacterium preparation, add MNNG, which is a typical base-substitution mutagen as a mutagen, to 5 μg / ml, and further add Mutation assay bacterium Salmonella typhimurium TA100 strain was added and shaken at 37 ° C. for 20 minutes in a shaking culture constant temperature water bath,
Pre-incubated. Top agar was then added and mixed, poured onto minimal glucose medium and spread evenly. After shading and culturing at 37 ° C. for 48 hours, the number of colonies of Salmonella typhimurium non-histidine-requiring strains generated by reversion was counted, and the antimutagenicity rate was calculated.

【0027】同様の方法で代表的なフレーム置換型変異
原物質であるTrp−P−2(0.05μg/ml)に
ついても抗変異原性率の試験を行ない、各乳酸菌試料の
抗変異原性能を測定した。
In a similar manner, the antimutagenicity rate of Trp-P-2 (0.05 μg / ml), which is a typical frame-substitution mutagen, was tested, and the antimutagenic performance of each lactic acid bacterium sample was tested. Was measured.

【0028】(c)この結果、各乳酸菌の変異原性率は
0%から77.1%までばらつきがみられたが、11種
150菌株以上の乳酸菌検体より、MNNGおよびTr
p−P−2の双方に高い抗変異原性を有する代表的菌種
として下記に示す7乳酸菌株を得た。 また、比較のた
め市販のヨーグルトから分離した乳酸菌5菌株について
も、同様の方法で測定した抗変異原性率を示す。
(C) As a result, although the mutagenicity rate of each lactic acid bacterium varied from 0% to 77.1%, MNNG and Tr were obtained from lactic acid bacterium specimens of 11 strains of 150 strains or more.
The following 7 lactic acid bacterium strain was obtained as a representative bacterial strain having high antimutagenicity to both p-P-2. For comparison, 5 lactic acid bacterium strains isolated from commercially available yogurt also show the antimutagenicity rate measured by the same method.

【0029】 [0029]

【0030】実 施 例 2 発酵乳(ヨーグルト)の製造とその抗変異原性試験:ヨ
ーグルトのスターターとして、実施例1において最も高
い抗変異原性を示した乳酸菌、ラクトバチルス・カゼイ
LA2株を、120℃で2秒間殺菌された牛乳に1%加
え、37℃にて16時間発酵させてヨーグルトを製造し
た。このヨーグルトについて、MNNG(5.0μg/
ml)およびTrp−P−2(0.05μg/ml)に
対する抗変異原性を下記の方法に従って調べた。 ま
た、比較のため、市販のヨーグルトについても同様に抗
変異原性率を測定した。この結果を下に示す。
Example 2 Production of fermented milk (yogurt) and its antimutagenicity test: As a starter of yogurt, the lactic acid bacterium Lactobacillus casei LA2 strain showing the highest antimutagenicity in Example 1 was used. 1% was added to milk sterilized at 120 ° C. for 2 seconds and fermented at 37 ° C. for 16 hours to produce yogurt. For this yogurt, MNNG (5.0 μg /
ml) and Trp-P-2 (0.05 μg / ml) were examined for antimutagenicity according to the following method. For comparison, the antimutagenicity rate was similarly measured for commercially available yogurt. The results are shown below.

【0031】( ヨーグルトの抗変異原性試験 ) (1) 滅菌した試験管に、試料ヨーグルトを0.1ml
とり、これに変異原物質としてMNNGを5μg/ml
となるように加える。 (2) これに、突然変異検定菌であるサルモネラ・チフ
ィムリウム(Salmonellatyphimurium)TA100株を
加え、振盪培養恒温水槽中、37℃で20分間振盪し、
プレインキュベートする。 (3) 次いで、トップアガーを加えて混合し、最少グ
ルコース培地の上に注ぎ、一様に広げる。 (4) 遮光し、37℃で48時間培養する。 (5) 復帰突然変異により生じたサルモネラ・チフィム
リウムのヒスチジン非要求株のコロニーの数を数える。 (6) Trp−P−2についても(1)〜(5)と同
様に抗変異原性試験を行なう。 ただし、(2)におい
て、Trp−P−2の量は0.05μl/mlとなる量
とし、さらにS9−mixを0.1ml加える。
(Anti-mutagenicity test of yogurt) (1) 0.1 ml of yogurt sample was placed in a sterilized test tube.
Then, add 5 μg / ml of MNNG as a mutagen.
To be added. (2) To this, 100 strains of Salmonella typhimurium TA, which is a mutation test bacterium, were added and shaken at 37 ° C. for 20 minutes in a shaking culture constant temperature water bath,
Pre-incubate. (3) Next, top agar is added and mixed, and the mixture is poured onto a minimal glucose medium and spread evenly. (4) Protect from light and incubate at 37 ° C for 48 hours. (5) Count the number of colonies of Salmonella typhimurium non-histidine-requiring strains generated by the back mutation. (6) For Trp-P-2, an antimutagenicity test is performed in the same manner as (1) to (5). However, in (2), the amount of Trp-P-2 was adjusted to 0.05 μl / ml, and 0.1 ml of S9-mix was further added.

【0032】 [0032]

【0033】実 施 例 3 ジュースの製造とその抗変異原性試験:実施例1と同様
にして遠心分離により集菌した、ラクトバチルス・カゼ
イLA2株の菌体に生理食塩水を加え、26億個/ml
に調製した。 この調製液を下記組成の、殺菌、冷却し
たジュースに加え、乳酸菌数を2.6億個/mlとし
た。
Example 3 Production of juice and its antimutagenicity test: physiological saline was added to the cells of the Lactobacillus casei LA2 strain collected by centrifugation in the same manner as in Example 1 to obtain 2.6 billion. Pieces / ml
Was prepared. This prepared liquid was added to sterilized and cooled juice having the following composition to adjust the number of lactic acid bacteria to 260 million / ml.

【0034】 ( ジュース組成 ) りんごジュース 880g ブドウ糖 10g 脱脂粉乳 10g ラクトバチルス・カゼイLA2株含有液 100g ───────────────────────────── ( 合 計 ) 1,000g(Juice composition) Apple juice 880 g Glucose 10 g Skim milk powder 10 g Lactobacillus casei LA2 strain containing liquid 100 g ────────────────────────── ─── (total) 1,000g

【0035】この乳酸菌入りりんごジュース 0.1ml
をとり、MNNGおよびTrp−P−2についての抗変
異原性を実施例2に準じて測定した。 この結果、本発
明ジュースのMNNGに対する抗変異原性率は71.3
%、Trp−P−2に対するそれは75.2%であっ
た。 以 上
0.1 ml of this apple juice containing lactic acid bacteria
The antimutagenicity of MNNG and Trp-P-2 was measured according to Example 2. As a result, the antimutagenicity rate of the juice of the present invention for MNNG was 71.3.
%, That for Trp-P-2 was 75.2%. that's all

───────────────────────────────────────────────────── フロントページの続き (72)発明者 森田 裕嗣 神奈川県横浜市旭区本宿町5番地 高梨乳 業株式会社商品研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Yuuji Morita 5 Honjuku-cho, Asahi-ku, Yokohama-shi, Kanagawa Takanashi Milk Products Co., Ltd. Product Research Laboratory

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 変異原物質に対する抗変異原性を有する
乳酸菌を含有する食品。
1. A food containing a lactic acid bacterium having antimutagenic activity against a mutagen.
【請求項2】 飲料である請求項第1項記載の食品。2. The food according to claim 1, which is a beverage. 【請求項3】 発酵乳または乳酸菌飲料である請求項第
1項記載の食品。
3. The food according to claim 1, which is fermented milk or a lactic acid bacterium beverage.
【請求項4】 乳酸菌がラクトバチルス・カゼイである
請求項第1項記載の食品。
4. The food according to claim 1, wherein the lactic acid bacterium is Lactobacillus casei.
【請求項5】 変異原物質が塩基置換型変異原物質およ
びフレームシフト型変異原物質の双方である請求項第1
項記載の食品。
5. The method according to claim 1, wherein the mutagen is both a base substitution type mutagen and a frameshift type mutagen.
Item food.
JP4075623A 1992-02-27 1992-02-27 Food containing lactic acid bacterium Pending JPH05236872A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4075623A JPH05236872A (en) 1992-02-27 1992-02-27 Food containing lactic acid bacterium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4075623A JPH05236872A (en) 1992-02-27 1992-02-27 Food containing lactic acid bacterium

Publications (1)

Publication Number Publication Date
JPH05236872A true JPH05236872A (en) 1993-09-17

Family

ID=13581533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4075623A Pending JPH05236872A (en) 1992-02-27 1992-02-27 Food containing lactic acid bacterium

Country Status (1)

Country Link
JP (1) JPH05236872A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07308170A (en) * 1994-05-18 1995-11-28 Shinguru Seru Shokuhin Kk Food improved in antimutagenic titer
WO2002053163A1 (en) * 2000-12-28 2002-07-11 Calpis Co., Ltd. Medicines for relieving intestinal disorders
JP2003534284A (en) * 2000-05-25 2003-11-18 カンパーニ ジェルヴェ ダノン Use of Lactobacillus casei in immunostimulatory peptides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07308170A (en) * 1994-05-18 1995-11-28 Shinguru Seru Shokuhin Kk Food improved in antimutagenic titer
JP2003534284A (en) * 2000-05-25 2003-11-18 カンパーニ ジェルヴェ ダノン Use of Lactobacillus casei in immunostimulatory peptides
WO2002053163A1 (en) * 2000-12-28 2002-07-11 Calpis Co., Ltd. Medicines for relieving intestinal disorders
US7029670B2 (en) 2000-12-28 2006-04-18 Calpis Co., Ltd. Medicines for relieving intestinal disorders

Similar Documents

Publication Publication Date Title
US4187321A (en) Method for producing foods and drinks containing bifidobacteria
KR102028744B1 (en) Lactobacillus plantarum HY7717 strain having immune-enhancing activity, antioxidative activity and digestive fluid resistance and use thereof
KR100356672B1 (en) Novel Lactobacillus sp. Strain And Using The Same
US8088422B2 (en) Purified pyrroloquinoline quinone fortified food
CN110100899B (en) Method for preparing fermented soybean milk powder from lactobacillus fermentum, prepared fermented soybean milk powder and application
US4702922A (en) Fruit products containing lactic acid and process for the lactic acid fermentation of fruit products
US7326558B2 (en) Process for treating spirulina
Benkerroum et al. Development and use of a selective medium for isolation of Leuconostoc spp. from vegetables and dairy products
KR102032703B1 (en) Method for producing aronia fermentation product using Lactobacillus plantarum MIFI-SY3 strain
JP5197375B2 (en) Bacterial growth-promoting substance
JPS6119220B2 (en)
Zamanpour et al. Isolation and some basic characteristics of lactic acid bacteria from beetroot (Beta vulgaris L.)—A preliminary study
CN117987298A (en) Lactobacillus plantarum and method for preparing asparagus fermented beverage by using same
JP2020061977A (en) Novel lactic acid bacterium that belongs to streptococcus salivarius, and use of the same
KR100503570B1 (en) Novel Pediococcus pentosaceus EROM101 having immune enhancement, anticancer and antibacterial activities
JP3209784B2 (en) New Lactobacillus microorganisms
KR100661824B1 (en) -1 Lactobacillus brevis OPY-1 and fermented milk containing thereof
JPH05236872A (en) Food containing lactic acid bacterium
CN113907135A (en) Phellinus igniarius flavored yogurt and preparation method thereof
AU784920B2 (en) Carbon-containing additive for foodstuff fermentations and food compositions containing it
JP3261571B2 (en) Method for improving survival of bifidobacteria
KR102488052B1 (en) Leuconostoc mesenteroides WiKim0121 and kimchi prepared by using the same
CN110150387B (en) Method for preparing fermented soybean milk powder from paenibacillus, fermented soybean milk powder and application
JP2577692B2 (en) Method for improving survival of bifidobacteria
KR20170005993A (en) Leuconostoc mesenteroides YSM1219 and its use